SIGLEC10
Sialic acid-binding Ig-like lectin 10
As of the edition of 20 October 2026, SIGLEC10 (sialic acid-binding Ig-like lectin 10, UniProt Q96LC7) has 2 drugs tested at it and 2 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q96LC7
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Solved structures
- 3
- Disease areas
- Cancer; Immune system; Blood and lymph; Infections; Lungs and airways; Nutrition and metabolism; Skin and connective tissue; Urinary and reproductive
- Registered trials of its drugs
- 9
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| CD24FC | Stopped | Phase 3 | none listed |
| ONC-841 | Stopped | Phase 1 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Engaged | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Merck & Co. | Route A |
The other 1 company at SIGLEC10
In the product2 companies in all; 1 is not named here, and no score is.
See the 2 companies at SIGLEC10, ranked, with the facts behind eachRequest access. Nothing is shown until you do.